Quarterly Dividends, Collaborations, and New Distribution Agreements Highlight Potential Growth - Research Report on Life Technologies, Thermo Fisher Scientific, Agilent, Quest Diagnostics, and Zimmer Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, July 17, 2013 NEW YORK, July 17, 2013 /PRNewswire/ -- Today, Wall Street Reports announced new research reports highlighting Life Technologies Corporation (NASDAQ: LIFE), Thermo Fisher Scientific, Inc. (NYSE: TMO), Agilent Technologies Inc. (NYSE: A), Quest Diagnostics Inc. (NYSE: DGX), and Zimmer Holdings, Inc. (NYSE: ZMH). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Life Technologies Corporation Research Report On July 2, 2013, Life Technologies Corporation (Life Technologies) announced that its new Ion AmpliSeq Exome Kit delivers the best exome sequencing performance in the industry, with up to 98% of bases covered at 10x, and up to 96% of bases covered at 20x, for a single exome. Gregg Fergus, Ion Torrent President and COO, stated, "The Ion AmpliSeq Exome Kit with the Ion Proton System and the upcoming Ion Chef System for automated template and chip loading, provide an exome solution that is superior on nearly every metric for lab scientists, core lab directors and large genome centers." Fergus continued, "More importantly, we are still scaling and improving at an incredible pace each and every quarter." The Full Research Report on Life Technologies Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/d9de_LIFE] -- Thermo Fisher Scientific, Inc. Research Report On July 12, 2013, Thermo Fisher Scientific, Inc. (Thermo Fisher) announced that its Board of Directors has declared a quarterly cash dividend of $0.15 per share. Thermo Fisher reported that the dividends will be payable on October 15, 2013 to shareholders on record as of September 16, 2013. The Full Research Report on Thermo Fisher Scientific, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/45ea_TMO] -- Agilent Technologies Inc. Research Report On July 9, 2013, Agilent Technologies Inc. (Agilent) announced that the Shanghai Integrated Circuit Research and Development Center (ICRD) is utilizing the Company's Model Builder Program and Model Quality Assurance software for model extraction and verification at 45-nm process nodes. Shoumian Chen, Vice President of Shanghai ICRD, commented, "As a loyal Agilent customer, we are proud to be using MBP and MQA software." Chen added, "The major enhancements in MBP/MQA 2013.01 enable us to complete the tedious aspects of our modeling work much more efficiently. Model Reviewer, for example, allows us to standardize various aspects of device modeling in a team environment. Because it is based on Agilent's unified end-to-end device modeling platform, it ensures seamless data transfers during the modeling process." The Full Research Report on Agilent Technologies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/075f_A] -- Quest Diagnostics Inc. Research Report On July 10, 2013, Quest Diagnostics Inc. (Quest Diagnostics) announced its collaboration with the US Centers for Disease Control and Prevention (CDC) to improve public health analysis of hepatitis C screening, diagnosis, and treatment, based on analysis of the company's national hepatitis C virus diagnostic information. Jay Wohlgemuth, M.D., Senior Vice President of Science and Innovation at Quest Diagnostics, said, "Our collaboration with the CDC underscores the importance of using diagnostic information to derive useful insights enabling effective prevention, detection and management programs for diseases with a significant impact on public health." John W. Ward, M.D., Director of CDC's Division of Viral Hepatitis, stated, "With 3 million Americans living with hepatitis C and up to 3 out of 4 who don't know they are infected, increased testing is critical to ensure that those who are infected receive life-saving care and treatment." The Full Research Report on Quest Diagnostics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/0cb6_DGX] -- Zimmer Holdings, Inc. Research Report On July 10, 2013, Zimmer Holdings, Inc. (Zimmer) announced that it has started the distribution of the APEX Spine System, a comprehensive set of implants and instruments designed to safely and effectively correct a broad range of spinal deformities, as well as complex and degenerative spinal diseases. As per the terms of the long-term agreement with SpineCraft, Zimmer will exclusively market the APEX Spine System to healthcare organizations across the United States, Canada, Australia and New Zealand. Steve Healy, President of Zimmer Spin, commented, "The APEX Spine System represents a true union of intuitive design and engineering excellence." Healy continued, "These innovative implants and instrumentation offer powerful correction capabilities with excellent intraoperative flexibility. This state-of-the-art pedicle fixation system represents a natural fit for Zimmer Spine's expanding portfolio, enabling surgeons to meet the unique needs of their complex spine and deformity patients, as well as patients with degenerative pathologies." The Full Research Report on Zimmer Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/9cbd_ZMH] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE Wall Street Reports Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
Dupont Posts Fourth-Quarter Operating EPS of 71c, Meeting Estimates
Quarterly Dividends, Collaborations, and New Distribution Agreements Highlight Potential Growth - Research Report on Life
Press spacebar to pause and continue. Press esc to stop.